Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: a single-center, non-randomized analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis.

Hatakeyama S, Murasawa H, Narita T, Oikawa M, Fujita N, Iwamura H, Mikami J, Kojima Y, Sato T, Fukushi K, Ishibashi Y, Hashimoto Y, Koie T, Saitoh H, Funyu T, Ohyama C.

BMC Nephrol. 2013 Oct 12;14:222. doi: 10.1186/1471-2369-14-222.

2.

Clinical effects of the new phosphorus binder, bixalomer in hemodialysis patients switched from sevelamer hydrochloride.

Gen S, Sasaki T, Saito K, Nobe K, Nodaira Y, Ikeda N.

Ther Apher Dial. 2014 Jun;18 Suppl 2:8-12. doi: 10.1111/1744-9987.12228.

PMID:
24975889
3.

Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.

Akizawa T, Origasa H, Kameoka C, Kaneko Y, Kawasaki S; Bixalomer Study Group..

Ther Apher Dial. 2014 Apr;18(2):122-31. doi: 10.1111/1744-9987.12068.

PMID:
24720402
4.

Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms.

Ito K, Takeshima A, Shishido K, Wakasa M, Kumata C, Matsuzaka K, Nakajima Y, Ogata H.

Ther Apher Dial. 2014 Jun;18 Suppl 2:19-23. doi: 10.1111/1744-9987.12229.

PMID:
24975891
5.

Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.

Pai AB, Shepler BM.

Pharmacotherapy. 2009 May;29(5):554-61. doi: 10.1592/phco.29.5.554. Review.

PMID:
19397463
7.

Effects of switching from sevelamer hydrochloride to bixalomer on laboratory parameters in hemodialysis patients.

Furukawa K, Ikawa T, Yokoi S, Yokouchi S, Kato K, Ueno M, Takahashi J.

Ther Apher Dial. 2014 Jun;18 Suppl 2:2-7. doi: 10.1111/1744-9987.12227.

PMID:
24975888
8.

A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.

Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Chertow GM, Hirakata H.

Nephrol Dial Transplant. 2014 May;29(5):1053-60. doi: 10.1093/ndt/gft483.

PMID:
24376274
9.

A review article: sevelamer hydrochloride and metabolic acidosis in dialysis patients.

Oka Y, Miyazaki M, Takatsu S, Oohara T, Toda K, Uno F, Matsuda H.

Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):283-6. Review.

PMID:
19075639
10.

Clinical experiences of bixalomer usage at our hospital.

Shima H, Makino R, Hata K, Ban A, Funao K, Sugita S, Furumitsu Y, Inoue K, Yoshimoto M, Okamura M.

Ther Apher Dial. 2014 Jun;18 Suppl 2:13-8. doi: 10.1111/1744-9987.12203.

PMID:
24975890
11.

Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis—sevelamer hydrochloride, calcium carbonate, and bixalomer.

Sanai T, Tada H, Ono T, Fukumitsu T.

Hemodial Int. 2015 Jan;19(1):54-9. doi: 10.1111/hdi.12188.

PMID:
24980286
12.

Sevelamer hydrochloride dose-dependent increase in prevalence of severe acidosis in hemodialysis patients: analysis of nationwide statistical survey in Japan.

Oka Y, Miyazaki M, Matsuda H, Takatsu S, Katsube R, Mori T, Takehara K, Umeda Y, Uno F.

Ther Apher Dial. 2014 Feb;18(1):37-43. doi: 10.1111/1744-9987.12052.

PMID:
24499082
13.

Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage.

Oka Y, Miyazaki M, Takatsu S, Kunitomo K, Uno F, Maruyama M, Matsuda H.

Ther Apher Dial. 2007 Apr;11(2):107-13.

PMID:
17381531
14.

Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride.

Chen JB, Chiang SS, Chen HC, Obayashi S, Nagasawa M, Hexham JM, Balfour A, Junge G, Akiba T, Fukagawa M.

Nephrology (Carlton). 2011 Nov;16(8):743-50. doi: 10.1111/j.1440-1797.2011.01509.x.

PMID:
21854503
15.

Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.

Ramos R, Moreso F, Borras M, Ponz E, Buades JM, Teixidó J, Morey A, Garcia C, Vera M, Doñate MT, de Arellano MR, Barbosa F, González MT.

Perit Dial Int. 2007 Nov-Dec;27(6):697-701.

PMID:
17984434
16.

Long-term treatment of hyperphosphatemia with bixalomer in Japanese hemodialysis patients.

Akizawa T, Kameoka C, Kaneko Y, Kawasaki S; Bixalomer Study Group..

Ther Apher Dial. 2013 Dec;17(6):612-9. doi: 10.1111/1744-9987.12023.

PMID:
24330556
17.

Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.

Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan-Taber S, Heaton J, Duggal A, Kalra PA.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1125-30. doi: 10.2215/CJN.05161107.

18.

Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis.

Kasai S, Sato K, Murata Y, Kinoshita Y.

Ther Apher Dial. 2012 Aug;16(4):341-9. doi: 10.1111/j.1744-9987.2012.01071.x.

PMID:
22817122
19.

Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.

Ahmadi F, Shamekhi F, Lessan-Pezeshki M, Khatami MR.

Saudi J Kidney Dis Transpl. 2012 Sep;23(5):934-8. doi: 10.4103/1319-2442.100865.

20.

A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.

Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM; PA21 Study Group..

Kidney Int. 2014 Sep;86(3):638-47. doi: 10.1038/ki.2014.58.

Supplemental Content

Support Center